Skip to the search field
Skip to the main page content
Skip to the Accessibility Statement
Research.fi
Menu
Suomeksi
På svenska
In English
Home
Search
Science and Innovation Policy
Science and research news
In English
- 35 results
Publications -
35
search results
Skip to search results
Show as image
Filter results
Displaying results 1 - 10 / 35
10
50
100
results / page
What
publication
information is included in the service?
Icon
Publication name
Authors
Publication channel
Year
Publications information icon
Second-line targeted therapies after
nivolumab
-ipilimumab failure in metastatic renal cell carcinoma
Peer-reviewed
Open access
DOI
10.1016/j.ejca.2018.11.031
Auvray, Marie; Auclin, Edouard; Barthelemy, Philippe; Bono, Petri; Kellokumpu-Lehtinen, Pirkko; Gros...
European journal of cancer
2019
Publications information icon
Nivolumab
versus Everolimus in Advanced Renal-Cell Carcinoma
Peer-reviewed
Motzer, R. J.; Escudier, B.; McDermott, D. F.; George, S.; Hammers, H. J.; Srinivas, S.; Tykodi, S. ...
New england journal of medicine
2015
Publications information icon
Nivolumab
in Previously Untreated Melanoma without BRAF Mutation
Peer-reviewed
DOI
10.1056/NEJMoa1412082
Robert, Caroline; Long, Georgina V.; Brady, Benjamin; Dutriaux, Caroline; Maio, Michele; Mortier, La...
New england journal of medicine
2015
Publications information icon
Nivolumab
-associated pemphigoid-like blistering dermatosis after sun exposure
Open access
DOI
10.1111/dth.13970
Kluger, Nicolas; Harjama, Liisa; Makkonen, Timo; Vehmanen, Leena; Lappalainen, Katriina
Dermatologic therapy
2020
Publications information icon
Nivolumab
alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032):a multicentre, open-label, phase 1/2 trial
Peer-reviewed
Open access
DOI
10.1016/S1470-2045(16)30098-5
Antonia, Scott J.; Lopez-Martin, Jose A.; Bendell, Johanna; Ott, Patrick A.; Taylor, Matthew; Eder, ...
The Lancet Oncology
2016
Publications information icon
Nivolumab
-induced poliosis restricted to a ta- ttoo:A coincidental association?
DOI
10.1016/j.annder.2023.01.002
Kluger, N.; Marcaillou, M.; Sibaud, V.
Annales de dermatologie et de venereologie
2023
Publications information icon
Nivolumab
plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Peer-reviewed
Open access
DOI
10.1056/nejmoa1712126
Motzer, R;Tannir, N;McDermott, D;Arén, Frontera O;Melichar, B;Choueiri, T;Plimack, E;Barthélémy, P;P...
new england journal medicine
2018
Publications information icon
Nivolumab
Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma:CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results
Peer-reviewed
Open access
DOI
10.1200/JCO.19.00538
Sharma, Padmanee; Siefker-Radtke, Arlene; de Braud, Filippo; Basso, Umberto; Calvo, Emiliano; Bono, ...
Journal of clinical oncology
2019
Publications information icon
CheckMate 025 Randomized Phase 3 Study:Outcomes by Key Baseline Factors and Prior Therapy for
Nivolumab
Versus Everolimus in Advanced Renal Cell Carcinoma
Peer-reviewed
Open access
DOI
10.1016/j.eururo.2017.02.010
Escudier, Bernard; Sharma, Padmanee; McDermott, David F.; George, Saby; Hammers, Hans J.; Srinivas, ...
European urology
2017
Publications information icon
Nivolumab
versus everolimus in patients with advanced renal cell carcinoma:Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial
Peer-reviewed
DOI
10.1002/cncr.33033
Motzer, Robert J.; Escudier, Bernard; George, Saby; Hammers, Hans J.; Srinivas, Sandhya; Tykodi, Sco...
Cancer
2020
Second-line targeted therapies after
nivolumab
-ipilimumab failure in metastatic renal cell carcinoma
Peer-reviewed
Open access
DOI
10.1016/j.ejca.2018.11.031
2019
Nivolumab
versus Everolimus in Advanced Renal-Cell Carcinoma
Peer-reviewed
2015
Nivolumab
in Previously Untreated Melanoma without BRAF Mutation
Peer-reviewed
DOI
10.1056/NEJMoa1412082
2015
Nivolumab
-associated pemphigoid-like blistering dermatosis after sun exposure
Open access
DOI
10.1111/dth.13970
2020
Nivolumab
alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032):a multicentre, open-label, phase 1/2 trial
Peer-reviewed
Open access
DOI
10.1016/S1470-2045(16)30098-5
2016
Nivolumab
-induced poliosis restricted to a ta- ttoo:A coincidental association?
DOI
10.1016/j.annder.2023.01.002
2023
Nivolumab
plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Peer-reviewed
Open access
DOI
10.1056/nejmoa1712126
2018
Nivolumab
Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma:CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results
Peer-reviewed
Open access
DOI
10.1200/JCO.19.00538
2019
CheckMate 025 Randomized Phase 3 Study:Outcomes by Key Baseline Factors and Prior Therapy for
Nivolumab
Versus Everolimus in Advanced Renal Cell Carcinoma
Peer-reviewed
Open access
DOI
10.1016/j.eururo.2017.02.010
2017
Nivolumab
versus everolimus in patients with advanced renal cell carcinoma:Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial
Peer-reviewed
DOI
10.1002/cncr.33033
2020
Previous
1
2
3
4
Next
Displaying results 1 - 10 / 35
Page 1
Sort